Tenapanor free base

• CAT Number: I009751
• CAS Number: 1234423-95-0 (free base)
• Molecular Formula: C50H66Cl4N8O10S2
• Molecular Weight: 1145.044
• Purity: ≥95%
• Target: Na+/H+ exchanger 3 (NHE3) inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)
• InChIKey: DNHPDWGIXIMXSA-CXNSMIOJSA-N
• SMILES: O=S(C1=CC=CC([C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)=C1)(NCCOCCOCCNC(NCCCCNC(NCCOCCOCCNS(=O)(C4=CC=CC([C@@H]5CN(C)CC6=C5C=C(Cl)C=C6Cl)=C4)=O)=O)=O)=O

Tenapanor (CAT: I009751), also known as AZD-1722 and RDX 5791, is a compound that acts as an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3. NHE3 plays a crucial role in sodium regulation in the gastrointestinal tract and kidneys. Tenapanor has demonstrated a promising preclinical safety profile, with no major concerns about side effects. Currently, tenapanor is undergoing clinical trials to evaluate its efficacy and safety for potential therapeutic applications.

Reference

1: Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study. Clin Pharmacol Drug Dev. 2017 Mar 24. doi: 10.1002/cpdd.341. [Epub ahead of print] PubMed PMID: 28339149.2: Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacol Drug Dev. 2017 Mar 16. doi: 10.1002/cpdd.346. [Epub ahead of print] PubMed PMID: 28301096.